Role of cytotoxic tumor-infiltrating lymphocytes in predicting outcomes in metastatic HER2-positive breast cancer a secondary analysis of a randomized clinical trial

JAMA Oncology

Volumn 3, Issue 11, 2017, Pages

  Liu, Shuzhen ^a   Chen, Bingshu ^b   Burugu, Samantha ^a   Leung, Samuel ^a   Gao, Dongxia ^a   Virk, Shakeel ^b   Kos, Zuzana ^c   Parulekar, Wendy R ^b   Shepherd, Lois ^b   Gelmon, Karen A ^d   Nielsen, Torsten O ^a  

^a Genetic Pathology Evaluation Centre   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CD8 ANTIGEN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PROGRAMMED DEATH 1 RECEPTOR; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TAXOID; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CD8+ T LYMPHOCYTE; CLINICAL OUTCOME; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SCORING SYSTEM; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; AGED; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ENZYMOLOGY; IMMUNOLOGY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PACLITAXEL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, CYTOTOXIC; TAXOIDS; TIME FACTORS; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 85037601057     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.2085     Document Type: Article

References (45)

1. Andre F, Dieci MV, Dubsky P, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013;19(1):28-33.
2. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26(4) (suppl 12):60-70.
3. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58(13):2825-2831.
4. Stagg J, Loi S, Divisekera U, et al. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108(17):7142-7147.
5. Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122(3): 1066-1075.
6. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15(2):e58-e68.
7. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11): 783-792.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-1672.
10. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
11. Dushyanthen S, Beavis PA, Savas P, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13:202.
12. + T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536-1543.
13. + lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14 (2):R48.
14. + regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645-655.
15. + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29(15):1949-1955.
16. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2(7):e24720.
17. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28(1):105-113.
18. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983-991.
19. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544-1550.
20. Luen SJ, Salgado R, Fox S, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18(1):52-62.
21. Foekens JA, Martens JW, Sleijfer S. Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2–positive breast cancer? J Clin Oncol. 2015;33(7):673-675.
22. + T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology. 2011;58(7):1107-1116.
23. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126.
24. Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015;33(14):1574-1583.
25. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9(5):e1001216.
26. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101 (21):1446-1452.
27. Denkert C, Wienert S, Poterie A, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the International Immuno-Oncology Biomarker Working Group. Mod Pathol. 2016;29(10):1155-1164.
28. + tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014; 16(5):432.
29. Salgado R, Denkert C, Demaria S, et al; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-271.
30. Pruneri G, Vingiani A, Bagnardi V, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Ann Oncol. 2016;27(2):249-256.
31. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-867.
32. Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017;24(1):3-15.
33. Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354-1360.
34. Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448-454.
35. Fumagalli D, Venet D, Ignatiadis M, et al. RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial [published online September 29, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.3824
36. Perez EA, Thompson EA, Ballman KV, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 2015;33 (7):701-708.
37. Perez EA, Ballman KV, Tenner KS, et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2016;2 (1):56-64.
38. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-1570.
39. Sodergren SC, Copson E, White A, et al. Systematic review of the side effects associated with anti–HER2-targeted therapies used in the treatment of breast cancer, on behalf of the EORTC Quality of Life Group. Target Oncol. 2016;11(3):277-292.
40. Jhaveri K. MARIANNE: impact on current treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer and implications for the future. J Clin Oncol. 2017;35(2): 127-130.
41. Chan A, Delaloge S, Holmes FA, et al; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377.
42. Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci. 2016;37(12):1081-1096.
43. Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6(8):1609-1623.
44. Iams WT, Lovly CM. Molecular pathways: clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade. Clin Cancer Res. 2015;21(19):4270-4277.
45. Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17: 52.